Q32 Bio Inc. — Director's Dealing 2021

Jun 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2021-06-17

Reporting Person: GILLIS STEVEN (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-17	Option (Right to Buy)	$7.26	A	18000	Acquired	2031-06-17	Common Stock (18000)	Direct

Footnotes

F1: This option shall vest and become exercisable on the earlier of June 17, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.